Guest guest Posted December 5, 2005 Report Share Posted December 5, 2005 Has anyone seen the article in the MS Focus magazine (Fall, 2005 issue) relating to LDN? Apparently LDN is starting to get around! Bob Lake Quote Link to comment Share on other sites More sharing options...
Guest guest Posted December 5, 2005 Report Share Posted December 5, 2005 Bob, is it online? Or do you have a copy you could scan and send to the group? I tried looking for it, but couldn't find anything. Thank you. Quote Link to comment Share on other sites More sharing options...
Guest guest Posted December 6, 2005 Report Share Posted December 6, 2005 & Cris, I have scanned the article and sent it to the group address but apparently it did not go through and I did not get an “undeliverable” message. My scanner is in an office environment and the item gets scanned and is forwarded to my computer. I then “forward” it to the group address. Am I doing something wrong? I am going to type the article as it appeared in Volume 7, Issue 4, Fall 2005 of MS Focus which is distributed by the Multiple Sclerosis Foundation. Here it is: LDN UPDATE The First Annual Low Dose Naltrexone (LDN) Confrence was held at the New York Academy of Sciences on June 11, 2005. The agenda included a keynote message from Dr. Bihari, a New York City physician who is currently treating over 400 patients with MS with LDN. The agenda also included five panels of researchers, doctors, pharmacists, and LDN advocates. In 1984, the Food and Drug Administration approved naltrexone in a 50 mg. dose for helping heroin or opium addicts, by blocking the effect of these drugs on the body. Commercially available under the name ReVia, this drug has not yet been approved or involved in any clinical trials for treating MS. In 1985, Dr. Bihari first observed the effects of a low dose of naltrexone (LDN) on the immune system. Several years later, he observed the beneficial effects of LDN on his patients with cancer and autoimmune diseases, such as lupus. Dr. Jill , Professor of Gastroenterology at Penn State’s Hershey Medical Center, recently completed an open-label pilot feasibility study using LDN in Crohn’s disease. Pleased with the results of the study, she has submitted an application to the National Institutes of Health to conduct a larger placebo-controlled trial. If this comes to pass, it will be the first scientific clinical trial of LDN to be completed at a U.S. medical center. Following the First Annual LDN Conference, several attendees decided to begin a U.S. fundraising effort to further research into the effectiveness of LDN for MS. It is called the LDN For MS Research Trust. To learn more, visit www.ldninfo.org . Keep in mind that all information so far is anecdotal and has not yet been proven in any clinical trial. After reading the article again I guess it is pretty significant in a couple of areas. Dr. Jill has submitted an application to conduct a clinical trial AND the MS Foundation has indicated the following in their magazine: To learn more, visit www.ldninfo .org Bob Lake ! GROUPS LINKS Visit your group " low dose naltrexone " on the web. To unsubscribe from this group, send an email to: low dose naltrexone-unsubscribe Your use of is subject to the Terms of Service. Quote Link to comment Share on other sites More sharing options...
Guest guest Posted February 28, 2009 Report Share Posted February 28, 2009 From: szukidavis@... Sent: Sunday, February 22, 2009 2:16 PM cures for cancer , nySeville69@..., dwiedershine@..., MESAUG@... Subject: [cures for cancer] LDN ARTICLE > Immunomodulatory and Biochemical Effects of LDN > > LDN exerts its beneficial effects by reducing > inflammation and oxidative stress, modulating the > immune system, and inhibiting cancer cell > proliferation. > Naltrexone is an opiate antagonist that preferentially > blocks the mu opiate receptor found on neuroendocrine > and immune system cells. The consequences of this > blockage depend on its duration. That is, naltrexone’s > effects depend on how long the receptor is blocked. > HDN vs. LDN > High dose naltrexone (HDN) refers to naltrexone doses > greater than 10 mg daily. Low dose naltrexone (LDN) > refers to doses of naltrexone ranging from 1 to 10 mg > daily. > HDN blocks the opiate receptor continuously. This > persistent blockade prevents opiates, both endogenous > or naturally occurring opiate compounds and opiate > drugs, from reacting with the opiate receptor. > Consequently, opiate medications are prevented from > causing biochemical effects. > The endogenous opiate compounds, (the endorphins, > dynorphins, and metenkephalins) are also prevented > from causing their pleasurable effects. The natural > increase in endorphins caused by exercise, > acupuncture, chocolate, sunbathing, and lovemaking has > no effect in someone on HDN. > LDN blocks the opiate receptor for approximately 4 > hours. This intermittent blockade causes a rebound > effect resulting in a dramatic increase in endogenous > opiate production. > LDN Dosage > LDN is generally used in doses ranging from 3-10 mg > daily depending on body weight, the patient’s > condition, and individual response. For instance, > patients with multiple sclerosis (MS) and muscle > spasticity generally do better on a 3 mg dose than the > standard 4.5 mg dose recommended for neurodegenerative > disorders. > The most common side effects of LDN are sleep > disturbances and vivid dreams. These effects can be > avoided by taking LDN in the morning. Although early > reports suggested that LDN needed to be taken at > night, studies have shown that LDN can be taken at any > time. It is not necessary to take it at night. > > The Effects of LDN > The Pennsylvania State University researcher, Dr. Ian > Zagon, Ph.D. has been studying LDN for 25 years and > reports that LDN’s most important effect is its > ability to increase production of met-5-enkephalin, > which he named opioid growth factor (OGF) for its > functional properties. The endogenous opiates are > neurotransmitters as well as cytokines, influencing > the activities of immune system cells and having > distinct biochemical effects (e.g. growth factors, > neurotrophic factors, antiviral activity, anti-tumor > activity, anti-inflammatory and pro-inflammatory > effects). > > OGF forms a complex or system when it reacts with the > OGF receptor, a receptor found on immune system cells > and cancer cells. This system inhibits inflammation > and cancer cell growth. This system also restores > homeostasis, a natural process in which the body’s > cells and systems work together to maintain health. > Thus, LDN helps the body heal itself. In certain > cancers, OGF is used in place of LDN. > Dr. Jau-Shyong () Hong of the National Institute > of Environmental Health Sciences (NIEHS) discovered > that LDN also prevents microglial activation, the main > cause of chronic brain inflammation. In addition, LDN > has antioxidant properties that reduce the effects of > free radicals throughout the body, thereby reducing > chronic inflammation. > LDN also causes changes that reduce neuronal > degeneration. As a consequence, LDN offers protection > against neurodegenerative diseases, such as > Parkinson’s disease and MS. Chronic inflammation > contributes to the persistence of autoimmune disorders > and is an underlying cause of many conditions, > including Crohn’s disease. > By increasing endorphins, which are immunomodulators, > LDN improves immune function. Immunomodulators > stimulate antibody production in patients with > immunodeficiency (HIV infection) and reduce antibody > production in patients with excessive antibody > production (autoimmune disorders, herpes, Lyme > disease). > The Common Link > Doctors Zagon and Hong and other experts in the field > reported that diseases which respond favorably to LDN > are diseases that benefit from effects on cell > proliferation (cancer inhibition) or from a reduction > in inflammation (neurodegenerative and autoimmune > disorders, fibromyalgia) or that benefit from the > restoration of homeostasis and immunomodulation > (virtually all disorders, including infectious > diseases). > Clinical Trials > To date, LDN has been studied or is undergoing > clinical trials for pancreatic and head and neck > cancers, Crohn’s disease, HIV/AIDS, neuroblastoma, > melanoma, autism, Parkinson’s disease, lymphoma, > multiple sclerosis and fibromyalgia. There are also > many anecdotal reports that suggest LDN offers > benefits in a wide range of other autoimmune and > neurodegenerative diseases and malignancies. Clinical > trials are needed to confirm the anecdotal > reports. & #9830; > Resources: > Wilkinson, LDNers.org > Private conversations with Doctors Ian Zagon, Jarred > Younger, and Hong, January, 2008. > ************** A Good Credit Score is 700 or Above. See yours in just 2 easy steps! (htt p://pr.atwola.com/promoclk/100126575x1218822736x1201267884/aol?redir=http:%2F%2Fwww.freecreditreport.com%2Fpm%2Fdefault.aspx%3Fsc%3D668072%26hmpgID %3D62%26bcd%3DfebemailfooterNO62) Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.